JP2010528122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528122A5 JP2010528122A5 JP2010507678A JP2010507678A JP2010528122A5 JP 2010528122 A5 JP2010528122 A5 JP 2010528122A5 JP 2010507678 A JP2010507678 A JP 2010507678A JP 2010507678 A JP2010507678 A JP 2010507678A JP 2010528122 A5 JP2010528122 A5 JP 2010528122A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- polymer
- polymer composite
- groups containing
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims 37
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 20
- 239000002131 composite material Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000000376 reactant Substances 0.000 claims 12
- 230000027455 binding Effects 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000003446 ligand Substances 0.000 claims 10
- 229910052697 platinum Inorganic materials 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drugs Drugs 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 229910052783 alkali metal Inorganic materials 0.000 claims 5
- 150000001340 alkali metals Chemical class 0.000 claims 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 5
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 5
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 5
- 239000003381 stabilizer Substances 0.000 claims 5
- 108010016731 PPAR gamma Proteins 0.000 claims 4
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 4
- 102000014961 Protein Precursors Human genes 0.000 claims 4
- 108010078762 Protein Precursors Proteins 0.000 claims 4
- 239000002872 contrast media Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000003287 optical Effects 0.000 claims 4
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 4
- 208000000409 Breast Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 210000001072 Colon Anatomy 0.000 claims 3
- 210000004072 Lung Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000975 dye Substances 0.000 claims 3
- 230000002611 ovarian Effects 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 241000759909 Camptotheca Species 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N Coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 2
- 101700033006 EGF Proteins 0.000 claims 2
- 102100010813 EGF Human genes 0.000 claims 2
- 229940116977 Epidermal Growth Factor Drugs 0.000 claims 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 claims 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 229960005095 Pioglitazone Drugs 0.000 claims 2
- 210000002307 Prostate Anatomy 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M CHEMBL593252 Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 229960000304 Folic Acid Drugs 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- BBEAQIROQSPTKN-UHFFFAOYSA-N Pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000000999 acridine dye Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 229960000956 coumarin Drugs 0.000 claims 1
- 235000001671 coumarin Nutrition 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 125000005266 diarylamine group Chemical group 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000037320 fibronectin Effects 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000001022 rhodamine dye Substances 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000001018 xanthene dye Substances 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
Claims (37)
- 式(I)、式(II)及び式(III)から選択される少なくとも1つの繰り返し単位を有するポリマー複合体。
R1、R2、R3、R4、R5及び各R6はそれぞれ独立して水素、C1−10アルキル基、C6−20アリール基、アンモニウム基、アルカリ金属、多座配位子、保護された酸素原子を有する多座配位子前駆体、白金を含む基、薬物を含む基、標的化剤を含む基、光造影剤を含む基、磁気共鳴造影剤を含む基及び安定剤を含む基からなる群から選択され、
R1、R2、R3、R4、R5及びR6のうち、少なくとも1つは白金を含む基であり、
m、n及びoはそれぞれ独立して1又は2であり、
s、t及びuはそれぞれ独立して0又は≧1であり、ここで、s、t及びuの合計は≧1以上である。) - 該白金を含む基がA1及びA2の両方に結合する、請求項1のポリマー複合体。
- 該ポリマー複合体が架橋単位を有する、請求項1〜3のいずれか1項のポリマー複合体。
- 該架橋単位が白金を有する、請求項4のポリマー複合体。
- s+tは2以上であり、
uは0であり、
R1、R2、R3及びR4の少なくとも1つは白金を含む基であり、かつR1、R2、R3、及びR4の少なくとも1つは薬剤を含む基であり、該白金を含む基と薬剤を含む基は同じではない、請求項1〜5のいずれか1項のポリマー複合体。 - s+tは2以上であり、
uは0であり、
R1、R2、R3及びR4の少なくとも1つは白金を含む基であり、かつR1、R2、R3及びR4の少なくとも1つは多座配位子、保護された酸素原子を有する多座配位子前駆体、標的化剤を含む基、光造影剤を含む基、磁気共鳴造影剤を含む基及び安定剤を含む基からなる群から選択される、請求項1〜5のいずれか1項のポリマー複合体。 - 該ポリマー複合体が、該ポリマー複合体に対する白金の質量比で、約0.5%〜約50%(重量/重量)の範囲の総量の白金を含む、請求項1〜8のいずれか1項のポリマー複合体。
- 薬物は抗癌剤である、請求項1〜9のいずれか1項のポリマー複合体。
- 抗癌剤はタキサン、カンプトテカ及びアントラサイクリンからなる群から選択される、請求項10のポリマー複合体。
- タキサンはパクリタキセル及びドセタキセルからなる群から選択される、請求項11のポリマー複合体。
- カンプトテカはカンプトテシンである、請求項11のポリマー複合体。
- アントラサイクリンはドキソルビシンである、請求項11のポリマー複合体。
- 標的化剤はアルギニン−グリシン−アスパラギン酸(RGD)ペプチド、フィブロネクチン、葉酸、ガラクトース、アポリポ蛋白質、インスリン、トランスフェリン、繊維芽細胞増殖因子(FGF)、上皮細胞増殖因子(EGF)、及び抗体からなる群から選択される、請求項1〜14のいずれか1項のポリマー複合体。
- 光造影剤はアクリジン色素、クマリン色素、ローダミン色素、キサンテン色素、シアニン色素及びピレン色素からなる群から選択される、請求項1〜15のいずれか1項のポリマー複合体。
- 磁気共鳴造影剤はGd(III)化合物を含む、請求項1〜16のいずれか1項のポリマー複合体。
- 安定剤はポリエチレングリコールである、請求項1〜20のいずれか1項のポリマー複合体。
- m、n及びoの群のうち少なくとも1つが1である、請求項1〜21のいずれか1項のポリマー複合体。
- PPARγを活性化する作用因子をさらに含み、該PPARγを活性化する因子が、ロシジタグロン及びピオグリタゾンからなる群から選択される、請求項1〜22のいずれか1項のポリマー複合体。
- 該溶解した又は部分的に溶解したポリマー反応物を第3の反応物と反応させることをさらに含み、該第3の反応物が、多座配位子、保護された酸素原子を有する多座配位子前駆体、薬物を含む基、標的化剤を含む基、光造影剤を含む基、磁気共鳴造影剤を含む基、安定剤を含む基及びPPARγを活性化する作用因子からなる群から選択される少なくとも1つを有する、請求項24の方法。
- 該溶解した又は部分的に溶解したポリマー反応物を第4の反応物と反応させることをさらに含み、該第4の反応物が、多座配位子、保護された酸素原子を有する多座配位子前駆体、薬物を含む基、標的化剤を含む基、光造影剤を含む基、磁気共鳴造影剤を含む基、安定剤を含む基及びPPARγを活性化する作用因子からなる群から選択される少なくとも1つを有する、請求項24〜25のいずれか1項の方法。
- 該溶解した又は部分的に溶解したポリマー反応物をカップリング剤の存在下で反応させることをさらに含む、請求項24〜26のいずれか1項の方法。
- 溶媒は極性非プロトン性溶媒である、請求項24〜27のいずれか1項の方法。
- 溶解された又は部分的に溶解されたポリマー反応物を触媒の存在下で反応させることをさらに含む、請求項24〜28のいずれか1項の方法。
- 有効量の請求項1〜23のいずれか1項のポリマー複合体を含有する、病気又は症状の治療又は寛解のための医薬組成物。
- ロシジタグロンを含む基及びピオグリタゾンを含む基から選択される1種以上の化合物を投与することをさらに含む、請求項30に記載の医薬組成物。
- 有効量の請求項1〜23のいずれか1項のポリマー複合体を含有する、病気又は症状の診断のための医薬組成物。
- 病気又は症状は肺腫瘍、乳房腫瘍、結腸腫瘍、卵巣腫瘍、前立腺腫瘍、及びメラノーマ腫瘍から選択される、請求項30〜32のいずれか1項の医薬組成物。
- 病気又は症状は肺腫瘍、乳房腫瘍、結腸腫瘍、卵巣腫瘍、前立腺腫瘍、及びメラノーマ腫瘍からなる群から選択される、請求項30〜32のいずれか1項の医薬組成物。
- 有効量の請求項1〜23のいずれか1項のポリマー複合体を含有する、組織の一部を造影するための医薬組成物。
- 該組織は、肺腫瘍、乳房腫瘍、結腸腫瘍、及び卵巣腫瘍からなる群から選択される腫瘍からのものである、請求項35に記載の医薬組成物。
- 該医薬組成物が、静脈に投与のための形態である請求項30〜36のいずれか1項の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91685707P | 2007-05-09 | 2007-05-09 | |
PCT/US2008/063128 WO2008141111A2 (en) | 2007-05-09 | 2008-05-08 | Polymers conjugated with platinum drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010528122A JP2010528122A (ja) | 2010-08-19 |
JP2010528122A5 true JP2010528122A5 (ja) | 2011-06-16 |
Family
ID=39615788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010507678A Pending JP2010528122A (ja) | 2007-05-09 | 2008-05-08 | 白金薬剤と結合されたポリマー |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080279782A1 (ja) |
EP (1) | EP2155254B1 (ja) |
JP (1) | JP2010528122A (ja) |
CN (1) | CN101730549B (ja) |
DK (1) | DK2155254T3 (ja) |
HK (1) | HK1141462A1 (ja) |
TW (1) | TW200906440A (ja) |
WO (1) | WO2008141111A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
WO2007067417A1 (en) | 2005-12-05 | 2007-06-14 | Nitto Denko Corporation | Polyglutamate-amino acid conjugates and methods |
WO2008141110A2 (en) * | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
WO2008141107A2 (en) * | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Compositions that include a hydrophobic compound and a polyamino acid conjugate |
US20100093935A1 (en) * | 2008-10-15 | 2010-04-15 | Nitto Denko Corporation | Method of preparing polyglutamate conjugates |
CA2751068A1 (en) * | 2009-01-31 | 2010-08-05 | Igf Oncology, Llc | Anti-cancer protein-platinum conjugates |
WO2011075483A1 (en) * | 2009-12-16 | 2011-06-23 | Nitto Denko Corporation | Controlled synthesis of polyglutamic acid |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
EP2800586A1 (en) * | 2012-01-03 | 2014-11-12 | Invictus Oncology Pvt. Ltd. | Ligand-targeted molecules and methods thereof |
WO2013154707A1 (en) | 2012-04-12 | 2013-10-17 | Nitto Denko Corporation | Co-polymer conjugates |
ES2633765T3 (es) | 2012-05-07 | 2017-09-25 | Nitto Denko Corporation | Conjugados poliméricos con un ligador |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59186924A (ja) * | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | ヒト免疫グロブリン結合抗腫瘍剤 |
ATE26584T1 (de) * | 1983-07-01 | 1987-05-15 | Battelle Memorial Institute | In-vivo abbaubares polypeptid und dessen anwendung zur verzoegerten freigabe von medikamenten. |
US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
CS254355B1 (en) * | 1985-04-10 | 1988-01-15 | Vladimir Saudek | Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances |
CH667874A5 (fr) * | 1985-12-19 | 1988-11-15 | Battelle Memorial Institute | Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments. |
US6673347B1 (en) * | 1986-04-30 | 2004-01-06 | Gryphon Therapeutics | Polypeptide and protein derivatives and process for their preparation |
IN165717B (ja) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
DE3806795A1 (de) * | 1988-02-29 | 1989-09-07 | Schering Ag | Polymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US6517824B1 (en) * | 1990-05-14 | 2003-02-11 | University Of Medicine & Denistry Of New Jersey | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5660822A (en) * | 1990-05-14 | 1997-08-26 | University Of Medicine & Dentistry Of N.J. | Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use |
US5372807A (en) * | 1990-05-14 | 1994-12-13 | University Of Medicine And Dentistry Of New Jersey | Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use |
GB9013615D0 (en) * | 1990-06-19 | 1990-08-08 | Wellcome Found | Pharmaceutical compounds |
US6762188B1 (en) * | 1990-06-19 | 2004-07-13 | Smithkline Beecham Corporation | Pharmaceutically active benzoquinazoline compounds |
GB9120653D0 (en) * | 1991-09-27 | 1991-11-06 | Procter & Gamble | Dispensing agent |
US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
KR940003548U (ko) * | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
BR9405798A (pt) * | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
US5548064A (en) * | 1993-05-24 | 1996-08-20 | Biotech Australia Pty Limited | Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions |
US5449720A (en) * | 1993-05-24 | 1995-09-12 | Biotech Australia Pty Limited | Amplification of the VB12 uptake system using polymers |
JPH09500411A (ja) * | 1993-07-13 | 1997-01-14 | アボツト・ラボラトリーズ | 蛍光性ポリマー標識された接合体および中間体 |
GB2282384B8 (en) * | 1993-08-18 | 1997-09-04 | Europ Economic Community | Drug delivery agents incorporating mitomycin |
US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
US6713045B1 (en) * | 1995-06-02 | 2004-03-30 | Research Corporation Technologies, Inc. | Targeted magnetic resonance imaging agents for the detection of physiological processes |
US5762909A (en) * | 1995-08-31 | 1998-06-09 | General Electric Company | Tumor targeting with polymeric molecules having extended conformation |
DE19548114C2 (de) * | 1995-12-21 | 2000-04-27 | Deutsches Krebsforsch | Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether |
PL189698B1 (pl) * | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
JPH09255590A (ja) * | 1996-03-21 | 1997-09-30 | Japan Synthetic Rubber Co Ltd | 徐放性薬剤 |
US6030941A (en) * | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
US5929198A (en) * | 1996-07-16 | 1999-07-27 | Nalco Chemical Company | Biodegradable poly (amino acid)s, derivatized amino acid polymers and methods for making same |
US5900228A (en) * | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
US5965118A (en) * | 1997-04-18 | 1999-10-12 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
US6251866B1 (en) * | 1997-08-05 | 2001-06-26 | Watson Laboratories, Inc. | Conjugates targeted to the interleukin-2 receptor |
US6229009B1 (en) * | 1997-08-29 | 2001-05-08 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Polycarboxylic based cross-linked copolymers |
US6528061B1 (en) * | 1997-09-04 | 2003-03-04 | Pasteur Institut | Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions |
JP3390965B2 (ja) * | 1997-09-12 | 2003-03-31 | 理化学研究所 | 糖結合スフィンゴシンを含有するポリマー化合物 |
US6391336B1 (en) * | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
AU1688099A (en) * | 1998-12-24 | 2000-07-31 | Kyowa Hakko Kogyo Co. Ltd. | Pharmaceutical preparation |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US20040121954A1 (en) * | 1999-04-13 | 2004-06-24 | Xu Wuhan Jingya | Poly(dipeptide) as a drug carrier |
US20010041189A1 (en) * | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
US6600788B1 (en) * | 1999-09-10 | 2003-07-29 | Xilinx, Inc. | Narrow-band filter including sigma-delta modulator implemented in a programmable logic device |
EP1466627A1 (en) * | 1999-10-12 | 2004-10-13 | Cell Therapeutics, Inc. | Polyglutamate camptothecin conjugates |
US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
US6235264B1 (en) * | 1999-12-01 | 2001-05-22 | General Electric Company | Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents |
KR100729015B1 (ko) * | 2000-01-04 | 2007-06-14 | 어섹스 팔마큐티칼스 인코포레이티드 | N,o-아미도말로네이트 백금 착화합물 |
US7166733B2 (en) * | 2000-01-04 | 2007-01-23 | Access Pharmaceuticals, Inc. | O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes |
TR200202194T2 (tr) * | 2000-03-17 | 2003-01-21 | Cell Therapeutics, Inc. | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri |
US20020077290A1 (en) * | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
CA2411545A1 (en) * | 2000-06-14 | 2002-01-03 | Medarex, Inc. | Tripeptide prodrug compounds |
GB0018240D0 (en) * | 2000-07-25 | 2000-09-13 | Pharmacia & Upjohn Spa | Polymeric conjugates of antitumor agents |
ATE330619T1 (de) * | 2000-09-26 | 2006-07-15 | Toudai Tlo Ltd | Polymere mizelle mit darin eingeschlossenem cisplatin und ihre verwendung |
US7070797B2 (en) * | 2000-11-07 | 2006-07-04 | Dana Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers |
KR100924990B1 (ko) * | 2001-06-20 | 2009-11-04 | 니폰 가야꾸 가부시끼가이샤 | 불순물 함량을 감소시킨 블록 공중합체, 고분자 담체 및고분자 의약제제 및 그 제조 방법 |
US20030109432A1 (en) * | 2001-12-10 | 2003-06-12 | Zuo William W. | Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same |
US6939538B2 (en) * | 2002-04-11 | 2005-09-06 | Biomedical Research Models, Inc. | Extended release analgesic for pain control |
FR2840614B1 (fr) * | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
JP2004018494A (ja) * | 2002-06-19 | 2004-01-22 | Japan Science & Technology Corp | ブロック共重合体−薬剤複合体の製造法 |
US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
US6855695B2 (en) * | 2003-06-13 | 2005-02-15 | Vion Pharmaceuticals, Inc. | Water-soluble SHPs as novel alkylating agents |
US20050118718A1 (en) * | 2003-09-22 | 2005-06-02 | University Of Utah Research Foundation | Stabilization and controlled delivery of ionic biopharmaceuticals |
WO2005035003A2 (en) * | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
EP1695991B1 (en) * | 2003-12-10 | 2010-02-17 | TOUDAI TLO, Ltd. | Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same |
WO2005063304A2 (en) * | 2003-12-24 | 2005-07-14 | Board Of Regents, The University Of Texas_System | Poly (l-glutamic acid) paramagnetic material complex and use as a biodegradable mri contrast agent |
KR20050104152A (ko) * | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
TW200616604A (en) * | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
KR20080028415A (ko) * | 2005-07-12 | 2008-03-31 | 다이이찌 산쿄 가부시키가이샤 | PPARγ 애고니스트를 함유하는 의약 조성물 |
WO2007067417A1 (en) * | 2005-12-05 | 2007-06-14 | Nitto Denko Corporation | Polyglutamate-amino acid conjugates and methods |
US20080051603A1 (en) * | 2006-06-15 | 2008-02-28 | Cell Therapeutics, Inc. | Process for the preparation of poly-alpha-glutamic acid and derivatives thereof |
-
2008
- 2008-05-08 DK DK08769347.9T patent/DK2155254T3/da active
- 2008-05-08 EP EP08769347A patent/EP2155254B1/en not_active Not-in-force
- 2008-05-08 CN CN200880020323.XA patent/CN101730549B/zh not_active Expired - Fee Related
- 2008-05-08 US US12/117,604 patent/US20080279782A1/en not_active Abandoned
- 2008-05-08 JP JP2010507678A patent/JP2010528122A/ja active Pending
- 2008-05-08 WO PCT/US2008/063128 patent/WO2008141111A2/en active Application Filing
- 2008-05-09 TW TW097117163A patent/TW200906440A/zh unknown
-
2010
- 2010-08-23 HK HK10108048.3A patent/HK1141462A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010528122A5 (ja) | ||
JP2010526917A5 (ja) | ||
Xia et al. | pH-responsive gold nanoclusters-based nanoprobes for lung cancer targeted near-infrared fluorescence imaging and chemo-photodynamic therapy | |
Liang et al. | Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers | |
Zhu et al. | Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer | |
Yu et al. | Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis | |
Ernsting et al. | Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models | |
Ding et al. | Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer | |
JP2010526829A5 (ja) | ||
Zhang et al. | A PEG-Fmoc conjugate as a nanocarrier for paclitaxel | |
Zhang et al. | Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide | |
Huang et al. | Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment | |
JP2009518511A5 (ja) | ||
Zhao et al. | Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin | |
US20100093935A1 (en) | Method of preparing polyglutamate conjugates | |
Huang et al. | Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment | |
CN102319436A (zh) | 叶酸修饰的o-羧甲基壳聚糖-脱氧胆酸复合物及其制备方法与应用 | |
JP7164205B2 (ja) | キナ酸修飾ナノ粒子およびその使用 | |
TW201132357A (en) | Carbohydrate-polyamino acid-drug conjugates | |
Paraskar et al. | Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy | |
Xu et al. | Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer | |
Zhong et al. | αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo | |
CN103768080A (zh) | 一种抗耐药肿瘤的靶向制剂、制备方法及应用 | |
Yan et al. | Construction of size-transformable supramolecular nano-platform against drug-resistant colorectal cancer caused by Fusobacterium nucleatum | |
Fu et al. | A novel redox-responsive ursolic acid polymeric prodrug delivery system for osteosarcoma therapy |